457 related articles for article (PubMed ID: 11113278)
1. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system.
Ries M; Zenker M; Gaffney PJ
Thromb Res; 2000 Nov; 100(4):341-51. PubMed ID: 11113278
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.
Fleury V; Lijnen HR; Anglés-Cano E
J Biol Chem; 1993 Sep; 268(25):18554-9. PubMed ID: 8103046
[TBL] [Abstract][Full Text] [Related]
3. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
Pannell R; Gurewich V
Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889
[TBL] [Abstract][Full Text] [Related]
4. Kinetic studies on novel plasminogen activators. Demonstration of fibrin enhancement for hybrid enzymes comprising the A-chain of plasmin (Lys-78) and B-chain of tissue-type plasminogen activator (Ile-276) or urokinase (Ile-159).
Fears R; Dodd I; Ferres H; Robinson JH
Biochem J; 1990 Mar; 266(3):693-6. PubMed ID: 2139324
[TBL] [Abstract][Full Text] [Related]
5. Differences between neonates and adults in tissue-type-plasminogen activator (t-PA)-catalyzed plasminogen activation with various effectors and in carbohydrate sequences of fibrinogen chains.
Ries M; Easton RL; Longstaff C; Zenker M; Corran PH; Morris HR; Dell A; Gaffney PJ
Thromb Res; 2001 Aug; 103(3):173-84. PubMed ID: 11672579
[TBL] [Abstract][Full Text] [Related]
6. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
7. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
9. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis.
Suenson E; Lützen O; Thorsen S
Eur J Biochem; 1984 May; 140(3):513-22. PubMed ID: 6233145
[TBL] [Abstract][Full Text] [Related]
10. Kinetic studies on the effect of heparin and fibrin on plasminogen activators.
Fears R
Biochem J; 1988 Jan; 249(1):77-81. PubMed ID: 2449177
[TBL] [Abstract][Full Text] [Related]
11. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Jackson KW; McKee PA
Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
13. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
14. Effects of fibrinogen and fibrin on the activation of Glu- and Lys-plasminogen by urokinase.
Takada A; Takada Y; Sugawara Y
Thromb Res; 1984 Mar; 33(6):561-9. PubMed ID: 6539003
[TBL] [Abstract][Full Text] [Related]
15. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
Bakker AH; Nieuwenbroek NM; Verheijen JH
Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
[TBL] [Abstract][Full Text] [Related]
16. Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase.
Takada A; Shizume K; Cho M; Takada Y
Thromb Res; 1987 Feb; 45(4):371-81. PubMed ID: 2437668
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
[TBL] [Abstract][Full Text] [Related]
18. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984
[TBL] [Abstract][Full Text] [Related]
19. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
20. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
